Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2016-03-29 Regulatory Filings
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans. It includes details about the securities to be registered, the incentive option plan, and incorporates by reference prior filings including an Annual Report on Form 20-F. The document is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an announcement or proxy statement. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is a full registration statement, not a brief announcement or certification.
2016-03-29 English
FORM 20-F
Annual Report FY 2015
2016-03-29 English
SABBY 13G ORPN 3.23.16
Major Shareholding Notification
2016-03-23 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by Bio Blast Pharma Ltd. It details the terms of an offering of ordinary shares, including pricing, risk factors, use of proceeds, and other related information. The document is a formal disclosure for a capital raising event, specifically a share offering. It is not a financial report, earnings release, management discussion, or any other type of report. It is clearly a capital/financing update describing the offering of new shares and related details. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2016-03-18 English
FORM 6-K
Capital/Financing Update Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, Bio Blast Pharma Ltd., with the SEC. It details a capital raising transaction involving a registered direct offering of ordinary shares and private placement of warrants, including agreements with placement agents and institutional investors. The document includes descriptions of the securities offering, terms, fees, and related agreements. It does not contain financial statements or detailed financial performance data but rather an update on financing activities. The document length is 7915 characters, which is substantive and not merely an announcement of a report. The content clearly fits the category of a Capital/Financing Update, as it provides detailed information about the company's fundraising and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-03-18 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, BioBlast Pharma Ltd., with the SEC. It includes unaudited interim consolidated financial statements and Management's Discussion and Analysis (MD&A) for the six months ended June 30, 2015. Form 6-K is used to report interim or other periodic information by foreign private issuers. The presence of interim financial statements and MD&A indicates this is an Interim / Quarterly Report equivalent for a foreign issuer. The document length is 2254 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2016-03-17 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.